Rabbits are the third most commonly anaesthetised pet in the UK, however they have a seven times greater overall risk of perioperative death than dogs1.
Jurox says Alfaxan 10mg/ml solution for injection provides a wide safety margin, an excellent cardio-respiratory profile and is dosed to effect, making it an excellent choice for the anaesthetic induction of rabbits.
The company also says Alfaxan provides smooth and rapid induction and recovery, painless administration and good muscle relaxation with low impact on ventilation and blood pressure.
Richard Beckwith, country manager of Jurox (UK) Ltd said: "Rabbits are a growing pet population and increasingly play a more important part in UK vet practices, which is why Jurox has invested in research in this species.
"We are happy we can now support our vet and nurse clients by providing a new and reliable choice for induction of anaesthesia in pet rabbits that has been extensively trialed and researched.
"Alfaxan is a very versatile product as it is convenient for any type of situation, whether it is surgery on healthy animals or high risk patients such as pet rabbits. With Alfaxan we hope to make a contribution to the future of veterinary anaesthesia in the UK and are confident our clients will be able to deliver the best practice anaesthesia they believe in."
For more information, visit: Alfaxan.co.uk. Alternatively, contact your local Jurox technical sales representative, telephone the customer services team on 0800 500 3171 or e-mail: info@jurox.co.uk.
References
Publishing Editor Arlo Guthrie said: "I've lost count of the number of vets who remark that all veterinary recruitment adverts say that there's a 'happy working team' or a 'supportive environment', or 'all the latest toys' and it's only when they arrive at the practice that they discover that everyone's at each other like ferrets in a sack, and the practice's idea of 'all the latest toys' is a 1972 Goblin Teasmade."
VetSurgeon Jobs now includes the ability for advertisers to display in their advert links to the VetSurgeon profiles of other employees at the practice who are prepared to have an informal chat with candidates about what it's like working there.
Using the messaging system on VetSurgeon.org, the potential applicant and the employee can then arrange a time for a chat, without revealing the employee's email address, after which the candidate will hopefully feel far better placed to decide whether it's the job for them.
Arlo said: "Of course, no advertiser is going to display the name of an employee who is going to say bad things about the practice, but it still offers the chance for candidates to ask questions and make their own mind up before applying for an interview."
Aside from that, just the fact that a practice shows that it has the confidence in its employees to put them in touch with potential candidates says something very positive about those practices which use the feature.
To use the new feature, job advertisers need to enter the email address of another employee at the practice who is also a member of VetSurgeon.org and has agreed to talk to candidates, when they place their advertisement. When it goes live, the advert will then contain a direct link to the employee's profile, under the title: "Talk to other employees of this practice."
Bayer Animal Health has launched Renalzin®, a feed additive for the management of Chronic Renal Disease (CRD), the leading cause of morbidity and mortality, especially in older cats1.
One-third of all cats over 15 years of age have CRD2, but the disease often remains undetected until the cat suddenly falls ill, by which stage 85% of kidney function may have already been lost3. The clinical signs are often subtle and non-specific, and diagnosis is complicated by the fact that changes in laboratory values occur relatively late in the disease.
Dr. Dennis Chew, specialist in veterinary urology and nephrology at the Ohio State University, said: "Most veterinary surgeons understand that CRD affects many cats, especially as they age, and is a leading cause of death. CRD is difficult to identify in early stages - early intervention with treatment can prevent progression of CRD to those with more serious kidney deficits. Restriction of dietary phosphorus intake is known to be a pivotal beneficial step in the stabilisation of CRD. Renalzin is a paste specifically formulated for cats that prevents dietary phosphate absorption across the intestine - a beneficial effect is gained when added to the cat's normal diet or to a veterinary renal diet".
The main ingredient of Renalzin is Bayer-registered Lantharenol® (lanthanum carbonate), a phosphate binder which binds to dietary phosphate within the gastrointestinal tract. According to the company, this renders it indigestible and thereby eases the burden on the already damaged kidneys.
Renalzin contains two additional ingredients - kaolin and vitamin E. Kaolin is a toxin binder which helps to reduce the absorption of toxins from the gastrointestinal tract. Vitamin E is known to reduce free radicals, improving immunity and protecting the integrity of cell membranes.
Bayer says that clinical studies demonstrate that Renalzin significantly increases faecal elimination and decreases urinary excretion of phosphorus 5. The product also decreases phosphate digestibility (absorption) in cats that are on both high and lower phosphate diets6. In addition, studies have shown that Renalzin causes a decrease in serum phosphate levels in cats with standard maintenance diets non-restricted in phosphorus7. Finally, a clinical trial in feline CRD patients revealed that taking Renalzin resulted in improvements in general clinical examination parameters as assessed by their veterinary surgeons over a two month period in cats on a normal diet7.
Renalzin comes in a pump applicator. One pump action provides 1 ml, with 2 ml being the recommended daily dose applied to and/or mixed with the cat's food. Having a neutral taste and being odourless, Renalzin® does not change the flavour of the cat's food and is flexible for clients to use as it can be given once or twice daily depending on the cat's feeding pattern.
References1 Lulich JP, O'Brien TD, Osbourne CA, Polzin DJ. Feline renal failure: questions, answers, questions. Cd Cont Ed Pract Vet 1992, 14(2): 127 - 151.2 Polzin DJ, Osbourne CA, Adams LG, Lulich JP. Medical management of feline chronic renal failure. In, Bonagura JD, Kirk RW (eds). Current Veterinarian Therapy X1. Philadelphia, PA, Saunders, 1992: 848-853.3 Grauer GF. Early detection of renal damage and disease in dogs and cats. Vet Clin Small Animal 2005, 35: 581-596.4 http://en.wikipedia.org/wiki/Lanthanum_carbonate.5 Schmidt B et al Bay 78-1887, J Vet Pharmacol Therap 2006, 29 (Suppl 1): 206-2076 Schmidt B, Spiecker-Hauser U, Gropp J. Effecrt of Lantharenol® on apparent phosphorus absorption from a conventional feline maintenance diet and a renal diet for cats. Proc Soc Nutr Physiol (2008) 17, in press.7 Data submitted for publication.
Genitrix has reformulated and repackaged its Lacto B range of broad spectrum probiotic supplements for the maintenance of normal digestive function in pets.
The products are provided in a powder formulation for direct application onto food or to be dissolved in water. They are available in five-day sachets or in 75g tubs suitable for longer term use.
Genitrix says that unlike single-strain formulations, the Lacto B range contains live freeze-dried cultures of three probiotic organisms which, when ingested, colonise the gut, helping to re-establish normal function. The three strains of probiotic organisms occupy the same sites in the gut as certain pathogenic bacteria thus preventing their attachment.
Indicated for dogs, cats, rabbits, rodents, reptiles and birds, the Lacto range is formulated to provide a guaranteed concentration of 1x109 CFU/g probiotic organisms.
Genitrix suggests that the Lacto B range can be particularly helpful in:
Rob Watkins, Marketing Director at Genitrix, said: "The Lacto range has been tried and trusted in small animal practice for twelve years and feedback shows that its multi-species indication make it a flexible and cost-effective solution."
"With its new formulation and new packaging, we believe it will prove even more attractive as a high potency probiotic supplement."
For more information, please click here.
Rominervin contains 10 mg/ml romifidine hydrochloride, equivalent to 8.76 mg romifidine, presented in a 20 ml vial.
It can be used as a sedative to facilitate handling, examination, minor surgical interventions and minor procedures or as a premedication prior to administration of injectable or inhalation anaesthetics.
Rominervin can also be used in combination with synthetic opiates such as butorphanol to provide deeper sedation or analgesia.
Dechra Brand Manager Emma Jennings said: "Rominervin is highly effective as it has a longer duration of action than other alpha-2 agonists1. It starts to work within one to two minutes with maximum sedation achieved between five and 10 minutes.
"It is yet another valuable addition in our equine anaesthesia and analgesia range that has been designed to provide vets with the therapies they need to operate successfully in day-to-day practice."
Rominervin can be used in conjunction with Dechra’s equine anaesthesia and analgesia app, designed to help veterinary professionals choose optimal anaesthetic protocols and calculate anaesthetic drug doses and administration rates.
For more information visit: www.dechra.co.uk/products/equine
The changes are designed to make the process more accessible and the College says most were proposed as a result of candidate feedback. They are:
The changes will come into effect from 1 January 2025, in time for the 2025 Stat Exam cohort.
Dr Linda Prescott-Clements, RCVS Director of Education, said: “We have been listening to the concerns of various stakeholders, including those who have undertaken the Stat Exam previously and veterinary employers, and we used this feedback to work with the Department for Environment, Food & Rural Affairs (Defra) to come up with a set of practical, deliverable changes that improve the experience of Stat Exam for all candidates, and hopefully alleviate some of the stress involved around timescales, opportunity and finance.
“These changes will make the exam more accessible, as it will allow candidates to have two attempts at the written papers within the same diet, which need to be passed before being allowed to proceed to the practical exam and it will also help improve accessibility to the exam from the perspective of candidate finances.
www.rcvs.org.uk/statutory-membership-exam
Written by members of BSAVA Scientific Committee, together with specialists in internal medicine and neurology, the document explains that there are limited studies showing beneficial effects of CBD, and those that there are need to be interpreted with caution as they involved small sample sizes and used unlicensed products which may have contained other components which could have influenced the results.
The document also explains that legally, CBD products must be prescribed by a veterinary surgeons and not used instead of a medication with proven efficacy.
Caroline Kisielewicz, BSAVA Scientific Committee member and one of the authors of the document said: “Information regarding the effects of cannabinoids on animals is predominantly at the stage of pre-clinical testing of individual substances in mice, rats and guinea pigs. There are limited clinical studies looking at the effects of CBD in dogs, and no reported studies in cats.
"There are many reports describing possible beneficial effects and therapeutic potential in humans, and subsequently pet owners may ask their vet about using cannabinoids to treat veterinary patients. This document aims to provide a broad overview of the available evidence base and legal position in the UK for veterinary team members."
BSAVA President, Ian Ramsey added: "The development of this information is in direct response to an increased interest in the use of CBD to treat cats and dogs. Furthermore, the guidance supports BSAVA’s mission to promote excellence in small animal practice through community, education and science."
The BSAVA position on CBD can be accessed here: https://www.bsavalibrary.com/content/chapter/10.22233/9781910443514.chap8#html_fulltext.
Headed by Esteban Gonzalez-Gasch, a European Specialist in Small Animal Surgery, the new department enables the practice to undertake a wide range of complex small animal procedures.
Injuries and conditions treated include fracture fixation, including complex and simple fractures; cruciate disease, including tibial osteotomies and extracapsular repair; arthroscopy; arthrodesis of chronically painful joints; elbow dysplasia; lameness investigation in adults and juveniles; treatment of growth deformities including distraction osteogenesis; osteoarthritis and musculo-skeletal neoplasia.
Esteban, who joined Southfields earlier this year from the leading Spanish veterinary hospital Ars Veterinaria, in Barcelona, said: "These new facilities really do put Southfields at the cutting edge of 21st century veterinary science and practice in the UK."
Southfields is also carrying out a full refurbishment of its existing facilities and recruiting a number of additional specialist veterinary surgeons, nurses and support staff.
Southfields’ operations manager Daniel Hogan said: "This is a very exciting period for us. We are growing in every possible area and working more closely with referring practices to continue to develop our bespoke and exceptional service for patients and clients.
"Our aim is aspiring and simple: to create the very best referral centre possible by bringing together the expertise of the very best of veterinary professionals supported by the very latest in technological innovation."
As well as orthopaedics, the practice accepts referrals in soft tissue surgery, internal medicine, oncology, neurology, feline medicine and cardiology. For more information, go to www.southfields.co.uk.
Equibactin oral powder comes in a 60g sachet, which Dechra says is the scientifically considered accurate dose1 for two daily treatments for a 600kg horse. The sachets come in a box of 10, which is sufficient for the twice daily treatment of a 600kg horse for five days.
The combination of sulfadiazine and trimethoprim antibiotics (known as TMPS) has a broad spectrum of uses and can be used to treat equine infections associated with Streptococcus and Staphylococcus aureus, gastrointestinal infections associated with E. coli and urogenital infections associated with beta-hemolytic streptococci.
Emma Jennings, Equine and Food Producing Animal Brand Manager, said: “Our product allows for twice daily 30mg/kg treatments, making the treatment of large horses easier and ensuring they receive the correct dose, which is crucial when it comes to tackling antibiotic resistance.”
She added: “TMPS is the only registered oral antibiotic available for use in horses and it is recommended as the first line of treatment for ‘common’ equine bacterial infections including those which have developed through wound infections or open or drained abscesses.2,3
“Effective antibiotics are an important part of the veterinarian’s arsenal when it comes to treating a variety of common bacterial infections in horses. But in recent years, the emergence of drug resistant bacteria has meant that extra precautions must be taken to prevent underdosing - one of the prominent causes of drug resistance.”
Equibactin oral powder is available now in the UK and Ireland. For more information visit www.dechra.co.uk.
The Association says that the total cost of claims, which was up 17% on the previous year, largely reflects the cost of veterinary treatment, drugs and diagnostic equipment, resulting in more expensive claims.
Three quarters of the claims were for dogs, and the most common high-value claim was for spinal surgery, costing £8,000 - £10,000.
One fifth of the claims were for cats and the remainder were for other pets.
Meanwhile, Go.Compare pet insurance has calculated that if all pet owners had been insured, the total cost of claims for veterinary treatment and other emergency fees could have reached over £11bn1.
Over the same period, the ABI says pet insurance premiums only rose by 1% to £327.
Michael qualified from the University of Glasgow in 2009 and then worked in first opinion practice in Buckinghamshire and Northern Ireland. He then returned to the University of Glasgow in 2012 to further his training and experience in oncology by completing four years of additional training. He completed an ECVIM residency in oncology in 2016 and became a Diplomate of the European College of Veterinary Internal Medicine and a European Specialist in Oncology in 2017. Michael worked at a private referral practice in Surrey prior to joining Fitzpatrick Referrals. Earlier this year, Michael was awarded a Masters degree in Veterinary Medicine. This additional qualification researched canine mast cell tumours.
Michael said: "I am absolutely delighted to have joined Fitzpatrick Referrals Oncology and Soft Tissue hospital. I have had a long-standing ambition to work as part of the fantastic team here since visiting the hospital during my specialist training in 2015. At this visit, I immediately felt at home in a group of people driven to deliver the very best compassionate care for dogs and cats.
"My ambition is to develop the very best ways to minimise the impact that cancer has on animals. I know that Fitzpatrick Referrals is the best environment for me to be able to achieve this. Throughout the hospital, there is an amazing positive attitude and a collective drive to improve the overall care we can give to pets with cancer. I am also excited by the opportunity to be able to help others to achieve their goals in improving cancer care for pets."
The charge against Dr Irvine was that in July 2017, he failed to discuss with the owners alternative treatment options to dental surgery under general anaesthetic, or the risks of dental surgery under general anaesthetic, and failed to obtain informed consent from the owners for the surgery.
Dr Vasilev was also originally charged with failing to discuss alternative treatment options or the risks of the surgery and failing to obtain informed consent. However, at the outset of the hearing, as a result of new information which came to light, the RCVS opted to offer no evidence in relation to these charges. Mr Vasilev was separately charged with failing to maintain clear, accurate and detailed clinical records in relation to his treatment of the dog.
At the outset of the hearing, Mr Irvine denied all aspects of the charge against him; while Dr Vasilev admitted all aspects of the remaining charge.
The Committee heard how Rupert's dental surgery under general anaesthetic was recommended by Mr Irvine on 10th July and performed by Dr Vasilev on 11th July 2017. After the surgery, Rupert was discharged, but vomited in his sleep that same night. He was brought back to the practice on 12th July, where Dr Vasilev administered antiemetic and antibiotic medication.
However, Rupert continued to vomit over the next five days, and was seen by the practice on 17th July and then on 18th when blood tests were conducted. Rupert’s condition deteriorated as he continued to vomit and lose weight and he was brought back to the practice on 22nd July where he was euthanased by Dr Vasilev.
The Committee heard evidence from Rupert’s owners as well as two expert witnesses. It found the first aspect of the charge against Mr Irvine proven on the basis that there was an inadequate discussion with the owners regarding the option of delaying the dental treatment on Rupert because of his recent ascites caused by congestive heart failure.
The Committee found the second aspect of the charge against Mr Irvine proven on the basis that he had not discussed the risks of Rupert undergoing general anaesthetic given the recent diagnosis of congestive heart failure, following which (in relation to the third aspect of the charge against Mr Irvine), it was therefore found proven that he had failed to gain informed consent.
With all aspects of the charge against Mr Irvine being proven, and with Dr Vasilev admitting the charge against him, the Committee went on to consider if the proven and admitted charges against both amounted to serious professional misconduct.
In respect of Mr Irvine, Stuart Drummond, chairing the Committee and speaking on its behalf, said: "The Committee was not persuaded that the failure to obtain informed consent from [the owner] and discuss matters further with her on 10th July 2017 in the circumstances of this case would amount to serious professional misconduct which would bring the profession into disrepute.
"In the Committee’s judgment, the breach of standards, whilst amounting to professional misconduct, was not serious professional misconduct, in the context of other discussions which had taken place…. The Committee further decided that a finding of serious professional misconduct in this case would be disproportionate having taken into consideration the discussions that Mr Irvine had with [the owner] prior to 10th July 2017 and the fact he was dealing with a complex and changing case.
"The Committee therefore found that Mr Irvine was not guilty of disgraceful conduct in a professional respect."
The Committee noted that Dr Vasilev had admitted breaching the Code of Professional Conduct for Veterinary Surgeons in respect of failing to keep adequate clinical and client records.
However, in mitigation, the Committee considered a number of factors including that, in failing to maintain adequate notes related to Rupert’s treatment, Dr Vasilev had followed the standard of notetaking in the practice as set out by Mr Irvine who was practice principal; that Dr Vasilev had only worked with Mr Irvine in the UK and his record-keeping was limited to working in one practice; that Dr Vasilev admitted his failures at an early stage of the proceedings; that he had made efforts to avoid repetition in the future by undertaking webinars and research; and, that he had shown insight into the need to ensure full communication and detailed note-taking.
Stuart Drummond added: "In relation to Dr Vasilev, the Committee was satisfied that [his] standard of record-keeping was in breach of the Code of Professional Conduct for Veterinary Surgeons and that the breach… amounted to professional misconduct.
"The Committee concluded that the breaches overall, when considering the context and number of mitigating factors, were, in the Committee’s view, insufficient to amount to serious professional misconduct…. Accordingly it found Dr Vasilev not guilty of disgraceful conduct in a professional respect."
The full facts and findings from the case can be found at www.rcvs.org.uk/disciplinary.
The RCVS Disciplinary Committee has directed that Somerset-based veterinary surgeon Dr Marcus Hutber be removed from the Register, having found him guilty of serious professional misconduct following multiple complaints made against him.
During the 11-day hearing, the Disciplinary Committee heard eight, separate and unrelated complaints against Dr Marcus Hutber, made whilst he was the owner of the veterinary company Epivet Ltd, with practices in Williton and Wiveliscombe, in 2009. The complaints involved a series of allegations including lack of adequate professional care, failure to have regard to animal welfare, failure to make or maintain adequate clinical records (and to provide them on request), and failure to treat clients with courtesy and respect.
In the first case, Dr Hutber was found to have performed surgery on a dog inadequately; failed to provide adequate post-operative pain relief; failed to obtain informed consent for the surgery from the dog's owner; and, failed to keep adequate clinical records of the dog's treatment. In a second case of inadequate professional care, Dr Hutber failed to ensure a cat's condition was monitored adequately; failed to ensure that the cat received appropriate fluid therapy; and, failed to keep adequate clinical records.
Dr Hutber was found to have brought the profession into disrepute by speaking rudely to one of his clients. On a separate occasion, a different client was found to have been treated without due courtesy or respect when Dr Hutber told her to come to the practice at once to get tablets and give them to her dog, otherwise the dog would die (of a disease he had diagnosed without carrying out the necessary investigations) - an instruction he then later repeated despite being told the dog was now being treated at a different practice.
One other complaint, where charges were proved, involved Dr Hutber's refusal to provide an animal's clinical records to a former client.
The Disciplinary Committee found Dr Hutber's conduct in respect of the charges proved in relation to each complaint, standing alone and taken collectively, amounted to serious professional misconduct.
In reaching its findings, the Committee considered the oral evidence and written statements of 20 witnesses (including Dr Hutber), two expert witness reports, a large quantity of documentary evidence, Dr Hutber's extensive rebuttal material and Counsels' submissions. Generally, the Committee preferred the evidence of the College's witnesses to that of Dr Hutber. Despite the Committee accepting he was of previous good character, it found him to be unhelpful and uncooperative, frequently lapsing into periods of silence that could last minutes, and staring fixedly (and, in the Committee's view, intimidatingly) at witnesses and College Counsel. There were also inconsistencies between his written rebuttal to the College, his witness statement and his oral evidence, about which the Committee found him evasive and illogical.
The Committee considered Dr Hutber had shown no insight into the allegations, or appreciated the significance or impact of his conduct upon his clients and their animals. He had shown no remorse or regret for his actions, and had continued to assert that he had done nothing wrong.
Further, he had caused actual injury to an animal by subjecting it to unnecessary revision surgery; displayed an inadequate and incomplete understanding of the concept of informed consent; demonstrated a lamentable lack of concern for animal welfare; brought the profession into disrepute with his treatment of his clients; and, exhibited conduct that fell far short of that to be expected of a member of the veterinary profession.
Chairing and speaking on behalf of the Committee, Professor Peter Lees, said: "The Committee has found that there were fundamental failings in the Respondent's clinical competence, and that there were serious defects in his interpersonal skills in relation to clients. He has throughout displayed a tendency to blame others for things which have gone wrong. [The Committee] is not satisfied that there is a realistic prospect of the Respondent having the ability or inclination to remedy his failings [and] remains unconvinced that there is a real possibility of a change in his attitude.
"The Committee is fully conscious that the purpose of sanction is not to punish, but to protect animals and the wider public interest and to uphold the reputation of the veterinary profession. Having regard to the serious aggravating factors [in this case], the Committee considers that the Respondent's conduct, taken as a whole, is so serious that removal of his professional status is the only appropriate sanction."
Accordingly, the Committee directed the Registrar to remove Dr Hutber's name from the Register.
The full details of the Committee's findings and decision are available on the RCVS website (www.rcvs.org.uk/disciplinary).
Dechra Veterinary Products has announced that it will be launching Zycortal, a new medication for the treatment of canine hypoadrenocorticism at the BSAVA Congress in April.
Zycortal is a prolonged-release suspension used as replacement therapy for mineralocorticoid deficiency in dogs with Addison’s disease. Dechra says it has proved highly effective in clinical trials with more than 80% of dogs responding positively to treatment1.
Zycortal contains desoxycortone pivalate (DOCP) which Dechra says controls serum electrolytes more effectively than fludrocortisone2 (the human treatment currently prescribed for dogs with Addison’s disease) and is considered the preferential drug for mineralocorticoid supplementation.
Zycortal is the only European licensed treatment for canine hypoadrenocorticism and adds to Dechra’s existing endocrinology range.
Visitors to the BSAVA Congress will be able to find out more about Zycortal at the Dechra stand (500). Delegates are also invited to attend a presentation by Professor Ian Ramsey BVSc PhD DSAM DipECVIM-CA FHEA MRCVS on Saturday, April 9, at 11.10am.
The presentation, New developments in the diagnosis and management of Addison’s disease aims to give delegates an insight into the condition.
Dechra Brand Manager Craig Sankey said: "We are very excited to be able to bring Zycortal to veterinary professionals in the UK. Addison’s disease can be very hard to diagnose as it mimics so many other illnesses.
"Each injection of Zycortal lasts approximately one month, providing long-term control of primary Addison’s disease. The prognosis for dogs with Addison’s disease is excellent provided that treatment is maintained for life. Our team will be on hand at the BSAVA Congress to explain and discuss the benefits that Zycortal can bring to their day to day practice in the fight against this illness."
Hysolv says the vaccine, which was developed by IDT Biologika, has been used successfully in Germany, where 1.7 million doses have been prescribed. The company says field trials have shown that vaccination not only protected against clinical signs of influenza but also resulted in improvements in reproduction and piglet performance.
Two 1 ml doses of the inactivated vaccine can be injected intramuscularly three weeks apart to pigs from 56 days old, providing immunisation to the majority of animals within seven days.
Hysolv director, Geoff Hooper said: "Swine flu can be devastating to a herd and this vaccine will broaden protection, particularly when used with our existing vaccine Respiporc FLU3, which we are strongly advising."
Respiporc FLU3 protects against three other strains of swine flu (H1N1, H1N2 and H3N2). Hysolv says that when used together, the two vaccines protect pigs against the most relevant strains in the British Isles.
Geoff added: "There have been several flu pandemics throughout the years – the latest in 2009. It is not possible to predict the emergence of a pandemic strain accurately but this vaccine combined with Respiporc FLU3 will greatly decrease the chance of pigs becoming infected."
Vetoquinol has announced the introduction of Melovem to the UK market. Melovem is a new injectable preparation containing 5mg/ml meloxicam which is licensed for use in pigs and young cattle.
According to the company, meloxicam is the most widely used veterinary non steroidal anti-inflammatory injection in the UK. Presented in 100ml bottles, with a lower dose formulation, Melovem can be a cost-effective NSAID solution to leave on-farm.
Mark Leddy from Vetoquinol said: "We are pleased to be the distributors of Melovem in the UK. Melovem provides vets and farmers with a new, cost-effective meloxicam injection that is suitable for on-farm use."
Contact your Vetoquinol representative for more information on Melovem, or call Vetoquinol on 0800 1608197.
Dr Kettle faced a charge that he had grabbed the dog, a Shih Tzu named Bella, when she was in a kennel, and/or failed to take sufficient care to ensure that Bella did not fall from her kennel, hit Bella with his hand and/or muzzle, and carried Bella only by her collar and/or scruff.
At the outset, Dr Kettle admitted that he had committed the acts as alleged and that his conduct represented serious professional misconduct.
Having taken evidence from the College and the respondent into account, the Committee considered that Dr Kettle’s actions had not only placed Bella at risk of injury but had also caused her actual injury evidenced by her tongue turning blue for a few seconds, the fact that she soiled herself and her stillness in the treatment room.
However, it also concluded that the incident was a single episode in respect of a single animal that had occurred over a period of 30 seconds, so whilst his actions were serious, they were not aggravated by being sustained or repeated over a period of time.
In terms of mitigating factors, the Committee considered that the circumstances at the time of the incident were relevant.
It found Dr Kettle to be a credible witness and accepted that, during the time that the incident occurred, he had been going through a very difficult time personally with the loss of locum staff, the increased work pressure during the pandemic and unrelated adverse comments on social media.
The Committee considered that whilst these factors did not excuse his behaviour, they had affected how Dr Kettle had reacted towards Bella on the day.
The Committee also noted from clinical records that Dr Kettle had been Bella’s veterinary surgeon for over seven years, on nine occasions prior to the incident and on seven occasions subsequently.
There has been no such evidence of any other incidents happening within this time. Dr Kettle received highly positive testimonials attesting to his usual high standards of practice, both before and since the incident, and the Committee was satisfied that this incident could properly be characterised as isolated and out of character.
Kathryn Peaty, Chair of the Disciplinary Committee and speaking on its behalf, said: “It was clear that Dr Kettle was deeply remorseful and ashamed of his actions, immediately recognising the seriousness of what he had done.
"Indeed, it was apparent to the Committee from Dr Kettle’s evidence that this remorse and regret continue to weigh heavily on him.
“In all the circumstances, although the Committee did not consider that Dr Kettle’s misconduct was at the lower end of the spectrum of seriousness, given the absence of future risk to animals or the public, and the evidence of exemplary insight, the Committee concluded that a reprimand was the appropriate and proportionate sanction in this case.
“The Committee was satisfied that a reprimand would mark Dr Kettle’s misconduct and reassure the public that veterinary surgeons who act as Dr Kettle had done, would face regulatory consequences and sanction.”
https://www.rcvs.org.uk/concerns/disciplinary-hearings
Mr Makepeace faced five charges.
The first charge was that in 2022 Mr Makepeace was convicted at Scarborough Magistrates Court of assaulting by beating his ex-partner.
He was sentenced to a community order and a curfew order and was ordered to pay a £95 surcharge and £85 in costs.
It was alleged that the conviction rendered him unfit to practise as a veterinary surgeon.
The second was that in August 2022, Mr Makepeace submitted a character reference which purported to have been written by his ex-partner saying that they "still live happily together", when this was untrue. It was also alleged that the reference purported to have been signed by Mr Makepeace's ex-partner when he knew that was not the case.
The third charge alleged that Mr Makepeace had sent WhatsApp messages to his ex-partner which were offensive, insulting, abusive, threatening and/or intimidating.
The fourth charge was that was a repetition of the second.
The fifth and final charge was that in relation to charges 2 and 4, that Mr Makepeace’s conduct was misleading and/or dishonest; and that it is alleged that in relation to charges 2,3,4 and/or 5, whether individually or in any combination, that Mr Makepeace was guilty of disgraceful conduct in a professional respect.
The first charge was proven by virtue of a certified copy of the memorandum of an entry in the Magistrates’ Court register.
Mr Makepeace also admitted the facts of all the other charges, meaning they were found proven by admission.
In terms of the conviction, the Committee assessed the incident to be serious – the assault was prolonged, involved strangulation and biting which led to physical injuries, and involved a pursuit.
This was found by the Committee to bring the reputation of the profession into disrepute.
The Committee therefore found that the conviction rendered Mr Makepeace unfit to practise.
With regard to the remaining charges, the Committee found Mr Makepeace’s behaviour serious, saying that it showed a blatant and wilful disregard of the role of the RCVS and the systems that regulate the veterinary profession, and that his actions were intended to dishonestly subvert that process.
The Committee considered that his actions fell sufficiently below the standards expected in terms of honesty and integrity, as well as in terms of the behaviour expected of a registered professional.
All this constituted disgraceful conduct in a professional respect.
When making a decision on the appropriate sanction, the Committee took into account evidence from Mr Makepeace, two character witnesses, and a document bundle including evidence of training, continuing professional development (CPD) and other testimonials.
Aggravating factors taken into account were:
Mitigating factors taken into account were that Mr Makepeace made full admissions at the start of the hearing; he expressed remorse; was shown to be of previous good character; that there had been a significant lapse of time since his conviction; he had made subsequent efforts to avoid repetition of the behaviour which led to the conviction; the financial impact upon Mr Makepeace if he was prevented from being able to practise; and the testimonials.
Neil Slater, Chair of the Disciplinary Committee and speaking on its behalf, said: “The Committee’s view was that the demands of the public interest in this case were high, and in light of all of the circumstances, removal from the register was the only means of upholding the wider public interest, which includes the need to uphold proper standards of conduct and performance, and to maintain confidence in the profession and its regulation.
“The Committee therefore decided to direct that the respondent should be removed from the Register.
"In coming to this decision, the Committee carefully applied the principle of proportionality and took into account the impact of such a sanction on the respondent’s ability to practise his profession, as well as the financial impact upon him, taking into account his evidence in this regard.
“However, the Committee determined that the need to uphold the wider public interest outweighed the respondent’s interests in this respect.
"In light of the gravity of the conduct, and all of the factors taken into account, any lesser sanction would lack deterrent effect and would undermine public confidence in the profession and the regulatory process.
"Removal was the only appropriate and proportionate sanction.”
The Royal College of Veterinary Surgeons has launched an online quiz to test its members' knowledge of the Guide to Professional Conduct.
The Guide outlines what is acceptable professional and ethical behaviour for veterinary surgeons. It is developed and maintained by the Advisory Committee of the RCVS, which, in addition to veterinary members of RCVS Council, also includes lay members, a member of the Veterinary Nurses Council, and independent (ie non-Council) veterinary surgeons. The Guide is the benchmark against which a veterinary surgeon is judged, by both the Preliminary Investigation and Disciplinary Committees.
The quiz, which was road-tested at the London Vet Show on 6-7 November, is anonymous, but the College will be collating data on results to help focus future communications activities and see where extra guidance may be required.
On completion of the quiz, it is possible to review answers and view the relevant section of the online Guide.
The quiz is aimed at veterinary surgeons: if it's a success, a version for Registered Veterinary Nurses will follow.
To try the quiz, visit www.rcvs.org.uk/guidequiz It will initially be online for three months and reviewed thereafter.
Shockwave therapy, or Extracorporeal shockwave therapy (ESWT) to give it its full nomenclature, sends mechanical shock waves into the affected area to stimulate the natural healing process by triggering the body’s own repair mechanisms.
The therapy is being spearheaded at Willows by Kinley Smith (pictured right), an RCVS and European specialist in small animal surgery. He said: "Shockwave therapy is a whole new line of treatment and has proved a spectacular success.
"It’s an excellent technique for dealing with certain orthopaedic conditions and there’s no invasive surgery, no wound to heal and no risk of infection so it really is a win-win-win procedure.
"It is particularly effective in the treatment of ligament and tendon injuries.
"There can be immediate pain relief for the dog; after two weeks we start to see lasting benefits and in four weeks we normally see a clear improvement.
"The added bonuses are we can normally reduce any medication; the dog can enjoy more exercise plus it is not as costly as undergoing an operation.
"Surgery is still essential in some of the more acute, problematic cases but shockwave therapy has been a terrific development in helping us provide an alternative treatment in a lot of soft tissue, muscle and bone conditions."
For more information, visit www.willows.uk.net.
One of the consequences of veterinary price inflation has been a backlash from owners against vets, vet nurses and receptionists, so the first film kicks off by explaining why large vet bills are not the fault of the vet standing in front of them when their dog gets ill.
Currently, a further eight films are now in production, each looking at a different reason why the costs of veterinary care have increased and suggesting ways that owners can mitigate the impact. They are:
VetSurgeon.org Publishing Editor, Arlo Guthrie, who presents the films, said: "Above all, the aim here is to foster a better understanding between veterinary professionals and owners.
"I do hope the vets, nurses and support staff who have been bearing the brunt will feel my films are helpful.
"If you do feel they make useful points, then you need to share and 'like' the hell out of them on all the different social media platforms, in order that they reach the largest number of people.
"And if you have feedback about the content, or ideas for other topics we should cover, then come and post here: https://www.vetsurgeon.org/f/non-clinical-questions/31062/why-have-vet-bills-gone-up-so-much/245723"
The film is available here:
TIKTOK: https://www.tiktok.com/@vetsurgeon.vetnurse/video/7426457335880617248
YOUTUBE: https://www.youtube.com/shorts/lg_EeamSbSI
FACEBOOK: https://www.facebook.com/reel/927062139289036
LINKEDIN: https://www.linkedin.com/posts/vetsurgeon-org_veterinarysurgeon-veterinarynurse-activity-7252420794004205568-LzE3/
INSTAGRAM: https://www.instagram.com/reel/DBM5i2XtfOB/
Fitzpatrick Referrals has announced the launch of a new cancer and soft tissue surgery referral service headed by Professor Nick Bacon (pictured right) and Dr Laurent Findji.
Professor Bacon and Dr Findji are American and European Board-Certified Surgeons respectively, with extensive experience in cancer care and soft tissue surgery innovation.
Professor Bacon joins the service directly from his post as Head of Oncology at the University of Florida, College of Veterinary Medicine. He will also take up the position of part-time Chair of Oncology at the new University of Surrey School of Veterinary Medicine.
Dr Findji joins the team from his prior role as director of the VRCC in Essex, bringing his expertise in cancer and soft tissue surgery advancements.
Professor Noel Fitzpatrick, founder of Fitzpatrick Referrals, said: "With these two eminent and globally recognised Specialists leading the new service, the UK will now be able to provide an innovative approach and comprehensive diagnosis, treatment, management and prognosis for all cancer and soft-tissue patients. The service will also be able to use the additional expertise available through the University of Surrey and both Specialists will be available for referring vets to discuss cases and to offer advice on the innovative treatment options available."
Professor Stuart Carmichael, the new service's director, said: "We would only introduce a service like this when we know it can provide the best options, the most comprehensive care and the highest level of expertise available. This is a referral service which will change the way that cancer patients are dealt with in the UK."
Noel added: "It's a testament to the reputation of Fitzpatrick Referrals and the University of Surrey, our partner in education, that we have been able to attract talents as great as Nick and Laurent. This is an exciting time not only for the hospital, but also for first-opinion practices throughout the UK who can avail of this world-class opportunity to offer a potentially life-saving service to their clients for their patients."
The service will operate initially from a self-contained clinic at the existing Fitzpatrick Referrals Orthopaedic + Neurology Hospital in Surrey and will be accepting patients from 1st October.
Almost half of the vets that watched a webinar about ferret medicine have said they would change their treatment protocols for adrenal disease and reproduction management as a result of what they learned.
The Virbac-sponsored webinar was led by John Chitty BVetMed CertZooMed CBiol MSB MRCVS and viewed by more than 600 practices, making it the most popular CPD event hosted by The Webinar Vet this year.
John Chitty said: "I provided an overview of treatment protocols for all of the common diseases but focused on adrenal disease as it's highly prevalent in neutered ferrets but may be reduced by the routine use of deslorelin implants. These implants can also be used to avoid surgical neutering."
According to a post-webinar questionnaire, 33% of clinicians said that they saw ferrets more than five times a year. Chris Geddes MRCVS, Product Manager at Virbac said: "This confirms what we thought: ferrets are being presented more and more in practice and so education on this species is vital. An amazing 41% of respondents said that they would change their protocols for reproduction management and 40% their treatment of adrenal disease following the webinar, showing how useful it was to those attending."
Virbac recently announced that it has gained a marketing authorisation for the use of Suprelorin 9.4mg in male ferrets. Suprelorin, a slow-release implant containing the gonadotropin-releasing hormone (GnRH) agonist deslorelin, offers temporary sterilisation without the need for surgery.
For those who were unable to see it at the time, the webinar can now be viewed by visiting www.virbac.co.uk. A CPD certificate is also available for download as are six other webinars previously sponsored by Virbac.
The company says Taurador Pour-on provides a stress-free, easy to use treatment, with persistent activity against a large number of cattle parasites, therefore ensuring effective coverage over long periods of the grazing season.
Matthew Swanborough BVSc MRCVS, Veterinary Advisor for Norbrook, said: "The farming industry will be aware that heavy worm burdens can significantly affect the health and productivity of cattle, potentially as much as £100 per head of cattle. We cannot simply ignore these parasites but we must tackle them responsibly. A comprehensive worming strategy is a vital component of any animal health plan, which should be composed of management strategies and any necessary anthelmintic treatments."
Norbrook highlights the product's efficacy against the gutworms Osterstagia osterstagi, Cooperia oncophora and lungworm, Dictyocaulus viviparous, with persistent action against these parasites for 35 days, 28 days and 42 days respectively.
Doramectin, the active ingredient in Taurador, is an anthelmintic belonging to the macrocyclic lactones (3-ML) group, along with ivermectins. Norbrook says both compounds share a wide spectrum of antiparasitic activity and produce a similar paralysis in nematodes and parasitic arthropods.
Dr Leigh Sullivan, Norbrook Large Animal Product Manager, said: "Taurador is the company’s thirteenth new product introduction in the last four years and it is a significant addition to our portfolio. Internal parasites such as gutworms and lungworm can have a serious impact on animal health and welfare, as well as financial implications for farmers, so it is great to be able to provide another product to help reduce the economic impact of these parasites."
Taurador is available in three different pack sizes (1L; 2.5L and 5L) and an appropriate dosing applicator is also available.
Morally injurious events are defined as experiences which violate one's moral or ethical code.
The research will consider the types of moral injuries veterinary professionals might encounter, their prevalence, the perceptions amongst professionals around how these moral injuries come about, and what support is needed when they occur.
The project is being led by psychologists Professor Neil Greenberg, Dr Dominic Murphy and Dr Victoria Williamson.
The research revolves around an online questionnaire which the researchers say should take no more than 20 minutes to complete: https://tinyurl.com/y7ue5ezw
Victoria said: “If you have experienced an upsetting event in your veterinary role, it would be really helpful if you could fill in our questionnaire which is anonymous and confidential. As part of this study, we are particularly interested in hearing about experiences that may have caused you to question the kind of person you are, or the kind of world we live in. These are things that you feel you may have done or failed to do, or things that others did or failed to do.
"We hope our results will help us to find better ways of meeting the needs of veterinarians in future so we would encourage veterinary professionals to also circulate this study to colleagues. Some participants may be invited to take part in a follow-up telephone interview; however, we would like to assure you this element of the project is completely voluntary.”
The survey will be followed by 1 hour telephone interviews with those who have indicated they are happy to be interviewed about their thoughts, feelings and beliefs since their challenging experience and how the event may have affected them.
The results of the study will be published in scientific journals and summaries will be made available for the relevant stakeholders with the aim of informing future research studies to support veterinary wellbeing, as well as clinical practice and policy.
Those who wish to find out more about the study before completing the survey can contact Victoria at: victoria.williamson@kcl.ac.uk